CYP2C19 LoF genetic variants (implying intermediate or low metaboliser status) have been shown to increase stroke and MI rates mainly in hospitalised patients with acute ischaemic conditions (or undergoing related interventions such as cardiac stents25), with little data on outcomes in primary care or over longer follow-up periods. This evidence concerns the gene CYP2C19 and stroke disorder.